David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).

Symptom Management

Alok A. Khorana, MD

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Multiple Myeloma

Sagar Lonial, MD, and Torben Plesner, MD

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Sagar Lonial, MD, of Emory University School of Medicine, and Torben Plesner, MD, of Vejle Hospital, discuss the latest findings on the use of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (Abstract 507).

Lymphoma

Olivier Casasnovas, MD

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577). To see the French language version of this video, please click here.

Multiple Myeloma

S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

S. Vincent Rajkumar, MD, of the Mayo Clinic, summarizes a special FDA-sponsored session on the three myeloma drugs that were approved this November––daratumumab, ixazomib, and elotozumab––and their current and future roles in treating the disease.

Nov

Today In Oncology

American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Sagar Lonial, MD, and Torben Plesner, MD, on Multiple Myeloma: Updated Results of the Phase I/II GEN503 Study

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study

S. Vincent Rajkumar, MD, on Multiple Myeloma: Newly Approved Drugs

Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds

OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?

Ponatinib/Blinatumomab Improves Event-Free Survival in Ph-Positive ALL

American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health

Izalontamab Brengitecan Improves Progression-Free Survival in EGFR-Mutated Advanced Nonsquamous NSCLC